Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Intralipid 20% Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
See Also
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. Intralipid will prevent the biochemical lesions of essential fatty acid deficiency (EFAD), and correct the clinical manifestations of the EFAD syndrome.
Intralipid 20% Indications
Indications
To provide a source of calories and essential fatty acids for patients requiring parenteral nutrition. To provide a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).
Intralipid 20% Dosage and Administration
Adult
Administer by IV infusion via a peripheral or central vein. Initiate rate at 0.2mL/kg/hr for the first 10–15mins; may gradually increase to required rate after 30mins (max: 0.5mL/kg/hr). Stable patients: initially 1g/kg/day; Critically ill patients: initially ≤1g/kg/day. Do not exceed 2.5g/kg/day; do not infuse >500mL on first day. Daily dose should not exceed a maximum of 60% of total energy requirements. EFAD: supply 8–10% of caloric input with Intralipid 20%.
Children
Administer by IV infusion via a peripheral or central vein. Birth to 2yrs (including preterm and term neonates): initially 0.5g/kg/day (max: 3g/kg/day); initiate rate at 0.1mL/kg/hr for the first 10–15min; may gradually increase to required rate after 15min (max: 0.75mL/kg/hr). 2–<12yrs: initially 1–2g/kg/day (max: 2.5g/kg/day); initiate rate at 0.2–0.4mL/kg/hr for the first 10–15min; may gradually increase to required rate after 15min (max: 0.75mL/kg/hr). 12–17yrs: initially 1g/kg/day (max: 2g/kg/day); initiate rate at 0.2mL/kg/hr for the first 10–15min; may gradually increase to required rate after 15min (max: 0.75mL/kg/hr). Daily dose should not exceed a maximum of 60% of total energy requirements. EFAD: supply 8–10% of caloric input with Intralipid 20%.
Intralipid 20% Contraindications
Contraindications
Known hypersensitivity to egg, soybean, or peanut. Severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride >1000mg/dL).
Intralipid 20% Boxed Warnings
Not Applicable
Intralipid 20% Warnings/Precautions
Warnings/Precautions
Risk of clinical decompensation with rapid infusion of IV lipid emulsion in neonates and infants: monitor closely the infant’s ability to eliminate the infused lipids from circulation (eg, measure serum triglycerides and/or plasma free fatty acid levels. Discontinue infusion if signs or poor clearance of lipids from circulation occur. Risk of parenteral nutrition-associated liver disease (eg, cholestasis or hepatic steatosis), other hepatobiliary disorders (eg, cholecystitis and cholelithiasis); monitor liver function and consider discontinuation or dose reduction if abnormalities occur. Correct severe fluid and electrolyte disorders prior to initiation. Measure serum triglycerides prior to initiation, with each dose increase, and regularly during therapy. Discontinue if hypersensitivity reactions or fat overload syndrome occur. Monitor for signs/symptoms of infection. Refeeding syndrome: monitor closely in severely malnourished and slowly increase nutrient intake. Patients with pulmonary edema, heart failure: monitor fluid status closely. Elderly. Pregnancy. Nursing mothers.
Intralipid 20% Pharmacokinetics
See Literature
Intralipid 20% Interactions
Interactions
Vitamin K content may antagonize anticoagulants (eg, coumarin, warfarin); monitor.
Intralipid 20% Adverse Reactions
Adverse Reactions
Intralipid 20% Clinical Trials
See Literature
Intralipid 20% Note
Not Applicable
Intralipid 20% Patient Counseling
See Literature
